Active surveillance testing to reduce transmission of carbapenem-resistant, gram-negative bacteria in intensive care units: a pragmatic, randomized cross-over trial.

Publisher: BioMed Central Country of Publication: England NLM ID: 101585411 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-2994 (Electronic) Linking ISSN: 20472994 NLM ISO Abbreviation: Antimicrob Resist Infect Control Subsets: MEDLINE

Original Publication: London : BioMed Central

Watchful Waiting* ; Bacteria*; Adult ; Humans ; Cross-Over Studies ; Gram-Negative Bacteria ; Carbapenems ; Intensive Care Units

Background: In intensive care unit (ICU) settings, the transmission risk of carbapenem-resistant, gram-negative bacteria (CRGNB) is high. There is a paucity of data regarding the effectiveness of interventions, including active screening, preemptive isolation, and contact precautions, to reduce transmission of CRGNB.
Methods: We conducted a pragmatic, cluster-randomized, non-blinded cross-over study in 6 adult ICUs in a tertiary care center in Seoul, South Korea. ICUs were randomly assigned to perform active surveillance testing with preemptive isolation and contact precautions (intervention) or standard precautions (control) during the initial 6-month study period, followed by a 1-month washout period. During a subsequent 6-month period, departments that used standard precautions switched to using interventional precautions and vice versa. The incidence rates of CRGNB were compared between the two periods using Poisson regression analysis.
Results: During the study period, there were 2268 and 2224 ICU admissions during the intervention and control periods, respectively. Because a carbapenemase-producing Enterobacterales outbreak occurred in a surgical ICU (SICU), we excluded admissions to the SICU during both the intervention and control periods and performed a modified intention-to-treat (mITT) analysis. In mITT analysis, a total of 1314 patients were included. The acquisition rate of CRGNB was 1.75 cases per 1000 person-days during the intervention period versus 3.33 cases per 1000 person-days during the control period (IRR, 0.53 [95% confidence interval (CI) 0.23-1.11]; P = 0.07).
Conclusions: Although this study was underpowered and showed borderline significance, active surveillance testing and preemptive isolation could be considered in settings with high baseline prevalence of CRGNB. Trial registration Clinicaltrials.gov Identifier: NCT03980197.
(© 2023. The Author(s).)

Infect Control Hosp Epidemiol. 1995 Dec;16(12):686-96. (PMID: 8683086)
Lancet Haematol. 2017 Dec;4(12):e573-e583. (PMID: 29153975)
Lancet Infect Dis. 2014 Jan;14(1):31-39. (PMID: 24161233)
N Engl J Med. 2011 Apr 14;364(15):1407-18. (PMID: 21488763)
N Engl J Med. 2001 May 10;344(19):1427-33. (PMID: 11346807)
Clin Infect Dis. 2021 Feb 1;72(3):431-437. (PMID: 31970393)
Infect Control Hosp Epidemiol. 2005 Feb;26(2):161-5. (PMID: 15756887)
Clin Infect Dis. 2007 Apr 15;44(8):1101-7. (PMID: 17366459)
Lancet. 2015 Mar 21;385(9973):1146-9. (PMID: 25150745)
Clin Infect Dis. 2005 Feb 1;40(3):405-9. (PMID: 15668864)
Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55. (PMID: 24329732)
Infect Control Hosp Epidemiol. 2003 May;24(5):362-86. (PMID: 12785411)
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S36-S40. (PMID: 28350902)
Ann Lab Med. 2017 May;37(3):231-239. (PMID: 28224769)
Clin Transplant. 2019 Sep;33(9):e13594. (PMID: 31102483)
PLoS One. 2012;7(4):e35564. (PMID: 22558168)

Keywords: Active surveillance testing; Carbapenem-resistant; Contact precautions; Gram-negative bacteria

ClinicalTrials.gov NCT03980197

0 (Carbapenems)

Date Created: 20230303 Date Completed: 20230307 Latest Revision: 20230310

20231215

PMC9983515

10.1186/s13756-023-01222-2

36869371